CD4-selective targeting of an antibody-polycation-DNA complex in the CD4 − K-562 cells. Using complexes syncomplex was investigated. The complex was synthesized thesised with the pGeneGrip vector, the transfection with the anti-CD4 monoclonal antibody B-F5, polylysine 268 efficiency in Jurkat and K-562 cells was examined using (pLL) and either the pGL3 control vector containing the confocal microscopy. More than 95% of Jurkat cells luciferase reporter gene or the pGeneGrip vector containexpressed GFP and the level of this expression was marking the green fluorescent protein (GFP) gene. B-F5-pLLedly enhanced by PMA. Negligible GFP expression was DNA complexes inhibited the binding of 125 I-B-F5 to CD4
+ seen in K-562 cells or when B-F5 was replaced by a nonJurkat cells, while complexes synthesised either without Bspecific antibody. Using flow cytometry, fluorescein-lab-F5 or using a non-specific mouse IgG1 antibody had little elled complex showed specific targeting to CD4 + cells in a or no effect. Expression of the luciferase reporter gene was mixed cell population from human peripheral blood. These achieved in Jurkat cells using the B-F5-pLL-pGL3 complex studies demonstrate the selective transfection of CD4 + and was enhanced in the presence of PMA. Negligible T-lymphoid cells using a polycation-based gene delivery luciferase activity was detected with the non-specific antisystem. The complex may provide a means of delivering body complex in Jurkat cells or with the B-F5-pLL-pGL3
anti-HIV gene therapies to CD4 + cells in vivo.
Keywords: CD4; HIV; gene transfer CD4, an integral membrane glycoprotein found on the surface of cells of lymphoid origin acts as a co-receptor in the T cell receptor complex, recognising foreign antigen in the context of MHC class II structures. 1 CD4 also has been identified as the primary cellular receptor for HIV 2, 3 and interaction of the HIV coat protein gp120 with this receptor is the first step in cell infection. The coreceptor CCR-5 or CXCR-4 then acts to trigger fusion of the virus with the cell membrane. [4] [5] [6] A number of strategies have been proposed to render CD4 + cells resistant to HIV infection. These include the expression of HIV specific antisense and ribozyme constructs, 7,8 expression of transdominant or dominant negative mutant forms of Tat, Rev or Gag [9] [10] [11] and recently, expression of intrakines targeting the co-receptors in CD4 cells. 12 While each of these approaches holds considerable therapeutic potential, the delivery of genetic material to CD4 + cells in vivo remains a major limitation. CD4 + cells have been targeted using Moloney murine leukemia virus and vesicular stomatitis virus with their respective Env elements replaced with recombinant gp160. 13, 14 CD4 + cells also have been targeted with liposomes incorporating gp120 15 and specific anti-CD4 antibodies on their surface. [16] [17] [18] [19] [20] been used to deliver anti-cancer agents, [16] [17] [18] as well as oligonucleotides 19, 20 to CD4 + cells. The present study characterises an anti-CD4 antibodypolycation-DNA complex that selectively targets CD4 + cells. Polycation-DNA complexes are relatively simple to produce and have been shown to deliver exogenous genes to a number of target cells. [21] [22] [23] Using luciferase assays in cell homogenates and green fluorescent protein (GFP) localisation by confocal microscopy, we found that the antibody-DNA complex was selectively taken up and expressed in the CD4 + cells. These findings may provide a means of delivery in vivo for anti-HIV gene therapies.
The anti-CD4 antibody used in this study was B-F5, a mouse anti-human mAb of the IgG1 isotype that recognises an epitope between amino acids 37 and 105 of the extracellular domain of the CD4 molecule. 24 B-F5 inhibits gp120 binding and rosette formation between CD4
+ COS cells and Raji B cells. 25 The antibody has been used in clinical trials for the treatment of autoimmune disorders such as rheumatoid arthritis, 26, 27 severe active multiple sclerosis, 24 Crohn's disease 28 and as prophylactic therapy to prevent rejection following transplantation. 29 Preliminary studies in this laboratory with B-F5 showed that it specifically bound to CD4 receptors on human Jurkat cells, CCRF-CEM cells and peripheral blood lymphocytes. Following binding, it was slowly internalised over 12-24 h (data not shown). The rate of binding and internalisation was similar to that described for a number of other anti-CD4 antibodies. 30, 31 Moreover, the rate of internalisation was significantly enhanced following phorbol ester treatment. It has been previously reported that the cytoplasmic domain of CD4 interacts with p56 lck of lymphoid cells, inhibiting constitutive internalisation of CD4 by inhibiting its aggregation in coated pits. 30, 32, 33 Phorbol esters disrupt CD4-p56 lck complexes increasing the rate of CD4 endocytosis. 34, 35 B-F5 was conjugated to poly(l)lysine 268 (pLL) using the heterobifunctional linker, N-succinimidyl 3-(2-pyridyldithio) propionate (SPDP) as previously described. 22, 23 The resulting B-F5-pLL conjugate was combined with plasmid reporter DNA to form a B-F5-pLL-DNA complex. The plasmid used was either the pGL3 control vector (Promega, Sydney, Australia) which contains the firefly luciferase gene, or the pGeneGrip vector (Gene Therapy Systems, San Diego, CA, USA) which contains the GFP gene. Ferkol and Perales 36,37 devised a multistep process for the formation of polycation-DNA complexes that involved increasing NaCl concentration, leading to the gradual condensation of DNA into compact unimolecular DNA-pLL complexes of uniform size and structure. Condensation of DNA has been reported to afford greater transfection efficiency 38, 39 and can protect the DNA from nuclease degradation. This technique was used to make complexes in the present study.
pLL-DNA complexes were formed at a 1:10 ratio of DNA to pLL and the concentration of NaCl required to achieve dissipation of unimolecular complexes (0.8-1.1 m, as determined by UV spectroscopy) was similar to that observed by Perales and colleagues. 40 The final complex consisted of 40 molecules of B-F5 and 10 molecules of pLL for each molecule of DNA.
To determine whether B-F5 in the complex retained CD4 receptor recognition, competition binding studies were performed using Jurkat cells. The B-F5 conjugate and complex significantly inhibited 125 I-B-F5 binding to a similar extent as that seen with unlabelled antibody (Figure 1) . By contrast, a conjugate or complex synthesised with a non-specific murine antibody of isotype IgG1 did not affect 125 I-B-F5 binding. These results show that modification of B-F5 to form complexes did not markedly affect CD4 binding.
The B-F5-DNA complex containing the luciferase reporter gene (pGL3 control vector) was transiently transfected into the CD4 − K-562 cell line and the CD4 + Jurkat cell-line using DEAE-dextran 41 to demonstrate expression of the complex. Under these conditions, expression of the reporter gene was slightly greater in K-562 cells (460 000 ± 70 000 luciferase activity units/10 6 cells) than in Jurkat cells (320 000 ± 10 000 luciferase activity units/10 6 cells). This experiment showed that the complex was able to be expressed in each cell line. The complex was then added to the cells in the absence of DEAE-dextran and the level of luciferase gene expression was determined 48 h later (Figure 2) . Little or no expression of the B-F5 complex was seen in the K-562 cells whereas significant expression was measured in the Jurkat cells. In addition, complexes constructed either without antibody or with a non-specific antibody showed only background levels of expression in the Jurkat cells. When cells were treated with phorbol myristate acetate (PMA) and the B-F5 complex, expression was significantly elevated in the Jurkat cells but not in the K-562 cells. Finally, PMA had no effect on the level of luciferase expression from constructs containing no antibody or the non-specific antibody. These experiments show that the B-F5-pLL-DNA complex was 
I-B-F5 in the presence of various antibody conjugates and DNA complexes. The conjugates and complexes were synthesized as follows: a 10-fold molar excess of SPDP in dimethylformamide (DMF) was added to 3.23 nmol B-F5 or non-specific antibody (1 mg/ml in PBS, pH 7.4) and incubated at 37°C for 30 min. This solution was dialysed overnight against 5 l PBS at 4°C. pLL (average MW approximately 57 000) in HEPES-buffered saline (150 mm NaCl, 10 mm HEPES, pH 8.0) was incubated with a 10-fold excess of SPDP in DMF at 37°C for 45 min. SPDP-modified pLL was desalted and reduced using a ReduceImm Reducing Column (Pierce Chemical, Rockford, IL, USA) to give pLL-SH. SPDP-modified B-F5 (or non-specific antibody) and pLL-SH (molar ratio of 4:1) were incubated at room temperature overnight on a rotating wheel. Aliquots of resulting solutions were analysed by SDS-PAGE. The

selectively expressed in the CD4
+ cells and that this specificity was determined by the anti-CD4 antibody.
To determine the extent of cell transfection by the antibody-DNA complex, a construct containing the GFP gene was used. Cells were treated as above and examined by confocal microscopy. Figure 3A shows the level of expression in Jurkat cells of a complex consisting of the reporter vector and pLL. Little or no expression was observed compared with the complex containing B-F5 ( Figure 3B) . Similarly, when B-F5 was replaced with a non-specific antibody, the level of GFP expression was markedly decreased ( Figure 3D ). The percentage of cells expressing GFP following treatment with the B-F5 complex was greater than 95%. When cells were treated with the B-F5 complex and PMA, GFP expression was not only enhanced, but it was also observed much earlier ( Figure  3C ). Finally, the B-F5 complex did not express in K-562 cells even in the presence of PMA ( Figure 3E ).
Dual-color flow cytometric analysis was used to determine the binding specificity of the complex to primary lymphocytes in peripheral blood. For these experiments, the B-F5-pLL conjugate was labelled with fluorescein iso- thiocyanate (FITC) and used to produce a complex (FITC complex). Human peripheral blood mononuclear cells (PBMC) were incubated with the complex and with phycoerythrin-labelled anti-human CD4 antibody (PE-CD4) which specifically labels CD4 + primary lymphocytes. The PE-CD4 used was clone Q4120 (Sigma Chemical, St Louis, MO, USA) which bound to a different epitope to B-F5, as determined by competition assays (data not shown). Figure 4a shows the flow cytometry of PMBC in the absence of either complex or PE-CD4. In the presence of PE-CD4 (Figure 4b ), approximately 11% of the cells showed specific binding of the antibody. A similar proportion of cells specifically bound FITC-complex ( Figure  4c ). When PBMC were incubated with both FITC-complex and PE-CD4 (Figure 4d ), nearly all of the CD4 + cells bound the complex, as shown by the shift in the cell population from the upper left quadrant to the upper right quadrant.
In the present study, a CD4 receptor targeted polycationic gene complex was constructed using the monoclonal antibody B-F5. The complex was shown to target CD4 + cells selectively with a transfection efficiency of greater than 95%. Moreover, the complex showed specific binding to CD4 + primary lymphocytes in PBMC. These investigations are the first demonstrating the selective transfection of CD4 + T lymphoid cells using a polycationmediated gene delivery system. The data also suggest 
